Kura Oncology Inc. (KURA)
Summary
KURA Chart
People also search for
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects
Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early commercial performance in relapsed/refractory NPM1-mutated AML. The company achieved $9.1M net product revenue in two quarters, marking a 57% sequential increase, and targets significant market expansion via first-line AML indications. Phase 3 KOMET-017 trial topline data in 2028 and two phase 1b KOMET-007 data readouts in 2H 2026 are key catalysts for pipeline expansion and valuation.
Kura Oncology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 425 | $4,415.82 | $4,024.75 | -$391.07 | -8.86% |
| NA Nizar Araji National Bank Of Canada /FI/ | 119 | $1,097.19 | $1,138.83 | $41.64 | 3.8% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 57,776 | $825,762.19 | $552,916.32 | -$272,845.87 | -33.04% |
| BG Bart Gancher Intech Investment Management LLC | 19,860 | $161,171.83 | $190,060.2 | $28,888.37 | 17.92% |
 Anthony Scaramucci SkyBridge Capital II LLC | 3.68M | $30.85M | $39.94M | $9.09M | 29.48% |
Kura Oncology Inc. (KURA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kura Oncology Inc. ever had a stock split?
Kura Oncology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Troy Wilson CEO | NASDAQ (NGS) Exchange | 50127T109 CUSIP |
| US Country | 260 Employees | - Last Dividend | - Last Split | 22 Sep 2015 IPO Date |
Overview
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel medicines for the treatment of cancer. With a strategic approach to cancer therapy, Kura Oncology leverages a pipeline of small molecule product candidates aimed at distinct cancer targets. Founded in 2014, the company is pioneering advancements in oncology, seeking to address unmet medical needs within the cancer treatment landscape. Headquartered in San Diego, California, Kura Oncology stands at the forefront of cancer research, aiming to deliver innovative solutions to patients worldwide.
Products and Services
- Ziftomenib
This product candidate is an orally bioavailable small molecule inhibitor specifically designed to disrupt the interaction between menin and KMT2A. Targeting genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), ziftomenib represents a promising avenue for the treatment of these challenging cancers.
- Tipifarnib
Tipifarnib is an oral farnesyl transferase inhibitor that has shown potential when used in combination with alpelisib for patients suffering from PIK3CA-dependent Head and Neck Squamous Cell Carcinoma (HNSCC). This innovative approach leverages the inhibition of farnesyl transferase to potentially overcome cancer cell growth and survival in specific patient populations.
- KO-2806
Serving as another farnesyl transferase inhibitor in Kura Oncology's arsenal, KO-2806 is currently being developed for the treatment of solid tumors. By targeting the same enzyme pathway as tipifarnib but with different properties, KO-2806 embodies the company’s commitment to diversifying its approach to cancer treatment through precision medicine.
In addition to its proprietary products, Kura Oncology has embarked on a clinical collaboration with Novartis Pharma AG. This partnership is dedicated to evaluating the combination of tipifarnib and alpelisib in a specific patient demographic with head and neck squamous cell carcinoma, highlighting the company's ongoing efforts to explore synergistic effects between different cancer therapies.
